Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca returns oncology programme rights to Infinity

This article was originally published in Scrip

Executive Summary

AstraZenecahas returned the rights to Infinity Pharmaceuticals' Hsp90 inhibitor programme after reviewing the products' potential and weighing up competing R&D investment priorities. The programme includes IPI-504 (retaspimycin hydrochloride for injection), which is currently in Phase III registration trials for patients with refractory gastrointestinal stromal tumours and oral IPI-493, which is in a Phase I study in patients with advanced solid tumours. Infinity will continue to develop the two products as it believes that with a prospective first-to-market Hsp90 inhibitor in late-stage development it can accelerate the timeframe for the company to achieve a meaningful commercial presence, Adelene Perkins, president and chief business officer, said. AstraZeneca will continue to fund an amount equivalent to its share of the Hsp90 programme costs for the next six months and Infinity will pay royalties on future net sales of IPI-504 and IPI-493. AstraZeneca acquired the worldwide rights to the two products when it acquired MedImmunelast year. MedImmune previously acquired the rights in August 2006.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts